Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296177 | PMC |
| http://dx.doi.org/10.3390/biomedicines11061769 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling the complexity of the impact of physical exercise on male reproductive functions: a review of both sides of a coin.
Front Physiol
December 2024
Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Oyo, Nigeria.
Regular exercise is widely recognized for its numerous physical and mental benefits, but its effects on male reproductive health are less understood. This review aims to summarize the current evidence on the impact of exercise on male reproduction, including reproductive hormone regulation, spermatogenesis sperm quality, and fertility. Moderate exercise improves sperm quality, increasing count, motility, and morphology, while excessive and severe exercise may have detrimental effects.
View Article and Find Full Text PDFThe effects of psychosocial aftercare following pediatric chronic pain treatment withstand the coronavirus disease 2019 pandemic: long-term outcomes of a randomized controlled trial.
Pain Rep
February 2025
German Paediatric Pain Centre, Children's and Adolescents' Hospital Datteln, Datteln, Germany.
Introduction: Intensive interdisciplinary pain treatment (IIPT) is the best therapy available for children and adolescents affected by severe chronic pain. Psychosocial aftercare (PAC) offered for 6 months after IIPT can improve treatment outcomes for up to 12 months.
Objectives: The current study is the first to explore whether PAC is superior to treatment as usual at a long-term follow-up of 18 to 33 months after discharge-including when facing the coronavirus disease 2019 (COVID-19) pandemic.
Geographical variation in high-impact chronic pain and psychological associations at the regional level: a multilevel analysis of a large-scale internet-based cross-sectional survey.
Front Public Health
December 2024
Department of Pain Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Background: A geographical analysis could be employed to uncover social risk factors and interventions linked to chronic pain. Nonetheless, geographical variation in chronic pain across different regions of Japan have not been well explored. This study aims to investigate geographical variation in high-impact chronic pain (HICP), defined as moderate to severe chronic pain, and examine the associated psychological factors at the prefecture level.
View Article and Find Full Text PDFEtiologic Pattern, Severity, and Outcome of Pericardial Effusion Among Children Seen Over Ten Years at a Tertiary Hospital in Sokoto, Northwest Nigeria.
Cureus
November 2024
Department of Medical Microbiology, Usmanu Danfodiyo University Teaching Hospital, Sokoto, NGA.
Introduction: Pericardial effusion (PE) is an abnormal accumulation of fluid in the pericardial space, which, if severe, is associated with high mortality. The causes are diverse, including infective and non-infective. Few studies have looked at the spectrum of severity and causes in Northern Nigeria.
View Article and Find Full Text PDFPemphigus vulgaris Treated With Rituximab: A Case Report.
Cureus
November 2024
Dermatology, Hospital Dr. Nélio Mendonça, Serviço de Saúde da Região Autónoma da Madeira (SESARAM), Funchal, PRT.
This case report highlights the efficacy of rituximab (RTX), a monoclonal antibody that targets B-lymphocytes, in the treatment of severe pemphigus vulgaris (PV) that was unresponsive to multiple conventional therapies. A 44-year-old female presented with mucocutaneous lesions that had been progressing for 12 months, with a Pemphigus Disease and Area Index (PDAI) total activity score of 66, indicating severe disease. The patient received two infusions of RTX two weeks apart, without complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!